Gerulewicz-Vannini D, Camero Y, Salas J, Hernández-Andrade E

Language: Spanish
References: 22
Page: 228-233
PDF size: 73.04 Kb.

ABSTRACT

Objective. To compare the plasmatic levels of free testosterone (FT), total testosterone (TT), and dehydroepiandrosterone sulphate (DHEAs) obtained from women with pregnancy-induced hypertension (PIH) and from uncomplicated pregnant women in the third trimester of pregnancy. Methods. FT, TT and DHEAs were measured by radioimmunoassay in plasma samples from 30 women with PIH (PIH group) defined as mean blood pressure ≥ 105 mm Hg, and proteinuria ≥ 100 mg/dL and ‹ 300 mg/dL, and in 30 women with uncomplicated pregnancies (control group). Gestational age at the time of the study in the PIH group was 37 weeks +2 days (28+0 – 40+1), and in the control group, 37 weeks +1 day (28+0 – 41+6). The plasmatic androgen levels and the perinatal outcome were analysed in both groups. Results. There was no difference in the gestational age at birth. In the PIH group there were increased number of caesarean sections due to fetal distress (PIH group; n = 10, control group; n = 2; p = 0.05), lower birthweight (PIH group 2549 g [800-3400 g], control group 3242 g [2400-4200 g]; p = 0.02) and increased number of neonatal intensive unit care admissions (PIH group; n = 3, control group; n = 0). In the PIH group, FT and TT levels were significantly higher than controls (mean, SD) (FT PIH group, 5.94 (0.9) pg/mL; FT control group, 0.44 (0.2) pg/mL; p = 0.002. TT PIH group, 5.28 (2.4) nmol/L; TT control group, 3.6 (0.6) nmol/L; p = 0.02. There was no difference in DHEAs levels between the groups (mean, SD) (PIH group, 51.13 (23.7) µg/dL; control group, 70.0 (13.5) µg/dL). Conclusions. In women complicated with PIH there is an increment in the plasmatic levels of FT and TT. This might contribute to the clinical findings and the adverse perinatal outcome observed in this patients.

REFERENCES

1. Saflas AF, Olson DR, Franks AL, Agash HK, Pogras R. Epidemiology of preeclampsia and eclampsia in the United States. Am J Obstet Gynecol 1990; 163: 460-5.

2. Sibai BM. Eclampsia IV. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163: 1049-54.

3. ACOG practice bulletin. Diagnosis and Management of Preeclampsia and Eclampsia. Int J Obstet Gynecol 2002; 77: 67-75.

4. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179: 1359-75.

5. Gratacos E. Lipid-mediated endothelial dysfunction: a common factor to preeclampsia and chronic vascular disease. Eur J Obstet Gynecol Reprod Biol 2000; 92: 63-6.

6. Albrecht ED, Pepe GJ. Placental steroid hormone biosynthesis in primate pregnancy. Endocr Rev 1990; 11: 124-50.

7. Miller NR, Garry D, Cohen HW, Figueroa R. Serum androgen markers in preeclampsia. J Reprod Med 2003; 48: 225-9.

8. Ficicioglu C, Kutlu T. The role of androgens in the aetiology and pathology of pre-eclampsia. J Obstet Gynaecol 2003; 23: 134-7.

9. Acromite M, Mantzoros C, Leach R, Hurwitz J, Dorey L. Androgens in preeclampsia. Am J Obstet Gynecol 1999; 180: 60-3.

10. Serin IS, Kula M, Basbug M, Unluhizarci K, Gucer S, Tayyar M. Androgen levels of preeclamptic patients in the third trimester of pregnancy and six weeks after delivery. Acta Obstet Gynecol Scand 2001; 80: 1009-13.

11. Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D, Siiteri P, Hoover RN. Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. Int J Epidemiol 2003; 32: 455-60.

12. Jirecek S, Joura EA, Tempfer C, Knöfler M, Husslein P, Zeisler H. Elevated serum concentrations of androgens in women with pregnancy-induced hypertension. Wien Klin Wochenschr 2003; 115: 162-6.

13. Carlsen SM, Romundstad P, Jacobsen G. Early second-trimester maternal hyperandrogenemia and subsequent preeclampsia: a prospective study. Acta Obstet Gynecol Scand 2005; 84: 117-21.

14. Dereli D, Ozgen G, Buyukkececi F, Guney E, Yilmaz C. Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab 2003; 88: 2263-8.

15. Urman B, Sarac E, Dogan L, Gurgan T. Pregnancy in infertile PCOD patients. Complications and outcome. J Reprod Med. 1997; 42: 501-5.

16. Atamer Y, Erden AC, Demir B, Kocyigit Y, Atamer A. The relationship between plasma levels of leptin and androgen in healthy and preeclamptic pregnant women. Acta Obstet Gynecol Scand. 2004; 83: 425-30.

17. Young DS. Implementation of SI units for clinical laboratory data. Style specifications and conversion tables. Ann Intern Med 1987; 106: 114-29.

18. Salamalekis E, Bakas P, Vitoratos N, Eleptheriadis M, Creatsas G. Androgen levels in the third trimester of pregnancy in pa tients with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2005 [Epub ahead of print].

19. Savelieva GM, Efimov VS, Grishin VL, Shalina RI, Kashezheva AZ. Blood coagulation changes in pregnant women at risk of developing preeclampsia. Int J Gynaecol Obstet 1995; 481: 3-8.

20. Diamant YZ, Rimon E, Evron S. High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 1982; 143: 199-204.

21. Steier JA, Ulstein M, Myking OL. Human chorionic gonadotropin and testosterone in normal and preeclamptic pregnancies in relation to fetal sex. Obstet Gynecol 2002; 100: 552-6.

22. Laivouri H, Kaaja R, Rutanen E, Viinikka E, Ylikorkala O. Evidence of high circulating testosterone in women with prior preeclampsia. J Clin Endocrinol Metab 1998; 83: 344-7.